Cargando…

XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer

BACKGROUND: Approximately 60–80% of patients with advanced head and neck squamous cell carcinoma (HNSCC) die within five years after diagnosis. Cisplatin-based chemotherapy is the most commonly used palliative treatment for these patients. To evaluate the prognostic value of X-linked inhibitor of ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xi-Hu, Feng, Zhi-En, Yan, Ming, Hanada, Sayaka, Zuo, Hui, Yang, Cheng-Zhe, Han, Ze-Guan, Guo, Wei, Chen, Wan-Tao, Zhang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293890/ https://www.ncbi.nlm.nih.gov/pubmed/22403616 http://dx.doi.org/10.1371/journal.pone.0031601

Ejemplares similares

The long noncoding RNA XIAP-AS1 promotes XIAP transcription by XIAP-AS1 interacting with Sp1 in gastric cancer cells
por: Cai, Jun, et al.
Publicado: (2017)

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
por: Qu, Yang, et al.
Publicado: (2022)

Effect of matrine combined with cisplatin on the expression of XIAP in human rhabdomyosarcoma RD cells
por: Li, Li, et al.
Publicado: (2016)

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)
por: Guan, Jian, et al.
Publicado: (2016)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis
por: Qin, Hao, et al.
Publicado: (2012)

Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer
por: Alamgeer, Muhammad, et al.
Publicado: (2022)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP
por: Pang, Yingxin, et al.
Publicado: (2014)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)
por: Guan, Jian, et al.
Publicado: (2016)

Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway
por: Li, Xin, et al.
Publicado: (2019)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study
por: Visacri, Marília Berlofa, et al.
Publicado: (2017)

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer
por: Kim, Ka-Rham, et al.
Publicado: (2017)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis
por: Ma, Jie, et al.
Publicado: (2013)

High expression of PYCARD is an independent predictor of unfavorable prognosis and chemotherapy resistance in glioma
por: Liang, Aijun, et al.
Publicado: (2021)

AB268. Down-regulation XIAP expression enhances the sensitivity of RCC cells to apoptosis, but the basal expression of XIAP in apoptosis is stable
por: Yang, Wenzheng, et al.
Publicado: (2016)

Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma
por: Devleena,, et al.
Publicado: (2010)

Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin
por: Hsieh, Chen-Hsi, et al.
Publicado: (2013)

Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies
por: Jungbauer, Frederic, et al.
Publicado: (2022)

Adjuvant chemotherapy in head and neck cancer.
por: Stell, P. M., et al.
Publicado: (1990)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Malignant Myoepithelioma of the Head and Neck: Demographics, Clinicopathological Characteristics, Treatment, and Prognosis
por: Wang, Jia-Qi, et al.
Publicado: (2022)

Insonation of Systemically Delivered Cisplatin-Loaded Microbubbles Significantly Attenuates Nephrotoxicity of Chemotherapy in Experimental Models of Head and Neck Cancer
por: Chen, Hang-Kang, et al.
Publicado: (2018)

XIAP’s Profile in Human Cancer
por: Tu, Huailu, et al.
Publicado: (2020)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma
por: GAO, JIAN, et al.
Publicado: (2016)

Relationship of the expression levels of XIAP and p53 genes in hepatocellular carcinoma and the prognosis of patients
por: Li, Zhiqin, et al.
Publicado: (2017)

Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety
por: Qian, Xu, et al.
Publicado: (2015)

A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019)

BCAR3 promotes head and neck cancer growth and is associated with poor prognosis
por: Zhang, Ze, et al.
Publicado: (2021)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mt1gnb2m1u5a8uudrm08k68b53